Abstract:
Thyroid carcinoma is themost common malignancy of endocrine system. Different pathologicalclassifications of thyroid carcinoma differ greatly in biological behavior andprognosis. As a newly-emerging subject, molecular nuclear medicine has maderapid advances in both diagnosis and treatment of thyroid carcinoma. With theapplication of new imaging agents and devices such as SPECT/CT and PET/CT,molecular nuclear imaging can demonstrate, both qualitatively andquantitatively, the alterations in specific molecules of thyroid cancer oncellular and molecular level. Meanwhile, it is capable of utilizingradiopharmaceuticals to target specifically to these molecules. Here we presenta review on the latest progresses in this field.